STADA Arzneimittel AG / Change of Personnel
12.08.2008
Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Bad Vilbel, August 12, 2008 Effective August 13, 2008, the current Chief
Procurement, Production and Logistics Officer, Dr. Hans-Martin Schwarm, has
declared that he is leaving the Executive Board of STADA Arzneimittel AG
for personal reasons. The Supervisory Board and Executive Board have
regretfully accepted this decision and thank Dr. Schwarm for his many years
of service to the Group. Both committees have welcomed the fact that Dr.
Schwarm will continue to make his knowledge and experience available to the
company as a consultant. Dr. Schwarm had been an employee of the company
since 1992, a Member of the Executive Board since August 4, 2006 and had an
Executive Board contract until August 3, 2009. Dr. Schwarm's
responsibilities will be assumed by other Executive Board Members. Thus,
the Production and Quality Management area will in the future be under the
responsibility of Christof Schumann, Chief Research & Development Officer,
while the Production and Logistics area will belong to the area of
responsibility from Chief Financial Officer Wolfgang Jeblonski.
Also effective August 13, 2008, the current Chief Legal Officer Dr.
Alexander Oehmichen is leaving the Executive Board of STADA Arzneimittel AG
on the most agreeable terms. Dr. Oehmichen had been with the company since
2003, was a Member of the Executive Board since January 1, 2006 and had an
Executive Board contract until December 31, 2010. The Supervisory Board and
Executive Board would also like to thank Dr. Alexander Oehmichen for his
service to the Group. In the future, Dr. Oehmichen's responsibilities will
be assumed by Hartmut Retzlaff, Chairman of the Executive Board.
Thus, STADA's Executive Board now consists of three members: Chairman
Hartmut Retzlaff, Chief Financial Officer Wolfgang Jeblonski and Chief
Production and Development Officer Christof Schumann.
Further information:
STADA Arzneimittel AG / Corporate Communications / Stadastraße 218 /
D - 61118 Bad Vilbel / Phone: +49(0) 6101 603-113 /
Fax: +49(0) 6101 603-506 / E-mail: communications@stada.de /
Or visit our website at www.stada.com
DGAP 12.08.2008
---------------------------------------------------------------------------
Language: English
Issuer: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Deutschland
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf;
Freiverkehr in Berlin, Hannover, Hamburg, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: STADA Executive Board smaller
| Source: EQS Group AG